Access Pharmaceuticals Reports Significant Oral Bioavailability of Cobalamin(TM) Oral Insulin in Additional Studies
Access Pharmaceuticals announces closing of $6.3 million in registered direct offering
Access Pharmaceuticals raises $6.3 million in registered direct offering
Access Pharmaceuticals' Cobalamin oral insulin achieves greater than 80% oral bioavailability in preclinical models
Access Pharmaceuticals announces completion of ProLindac monotherapy trial and initiation of combination study